Cochrane Review Group

Kidney and Transplant

139 systematic reviews in Kidney and Transplant ask 2,434 questions. 20.7% have no studies to answer them, 25.1% rest on very low certainty evidence and 20.1% reach moderate or high certainty.

Reviews

139

Questions

2,434

current versions

No studies

20.7%

Moderate or high

20.1%

No studies 504 · 20.7%Ungraded 40 · 1.6%Very low 611 · 25.1%Low 790 · 32.5%Moderate 414 · 17%High 75 · 3.1%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Kidney and Transplant

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Valaciclovir vs ganciclovir or valganciclovir Acute rejection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.91 [0.22, 3.73]	3 studies · 271 participants	Very low
Low vs standard dose valganciclovir Opportunistic infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Low vs standard dose valganciclovir Adverse events · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Maribavir vs ganciclovir Graft loss · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Maribavir vs ganciclovir Opportunistic infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs placebo or no treatment Death (any cause) · people with IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Remission of proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Remission of haematuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Relapse of proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Death (any cause) · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Kidney failure · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Relapse of haematuria (macroscopic) · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	RR 1.33 [0.8, 2.23]	1 study · 32 participants	Very low

Reviews 139

Immunosuppressive treatment for proliferative lupus nephritis

Tunnicliffe, DJ, Palmer, SC, et al. · Cochrane Database of Systematic Reviews · 2018

Kidney and Transplant

Thinnest evidence

Reviews 139

Immunosuppressive treatment for proliferative lupus nephritis

Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD)

Biocompatible dialysis fluids for peritoneal dialysis

Antimicrobial lock solutions for preventing catheter‐related infections in haemodialysis

Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia

Effects of peri‐operative nonsteroidal anti‐inflammatory drugs on post‐operative kidney function for adults with normal kidney function

Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease

Antibiotics for asymptomatic bacteriuria in kidney transplant recipients

Treatment for hepatitis C virus‐associated mixed cryoglobulinaemia

Early versus late ureteric stent removal after kidney transplantation

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease

Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients

Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients

Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients

Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients

Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease

Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease

Glucose targets for preventing diabetic kidney disease and its progression

Probiotics for preventing urinary tract infection in people with neuropathic bladder

Ischaemic preconditioning for the reduction of renal ischaemia reperfusion injury

Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease

Peritoneal dialysis for acute kidney injury

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients

Dietary interventions for adults with chronic kidney disease

Antidepressants for treating depression in adults with end‐stage kidney disease treated with dialysis